Search alternatives:
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ms decrease » _ decrease (Expand Search), mean decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ms decrease » _ decrease (Expand Search), mean decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
26601
Image_2_T-Lymphocyte Subsets Alteration, Infection and Renal Outcome in Advanced Chronic Kidney Disease.TIFF
Published 2021“…The primary outcomes were the major infection and renal outcome.</p><p>Results: A total of 410 CKD patients were enrolled; the average age was 47.25 years. …”
-
26602
DataSheet_1_WASp Deficiency Selectively Affects the TCR Diversity of Different Memory T Cell Subsets in WAS Chimeric Mice.zip
Published 2022“…Bioinformatic analyses showed that compared with wild type (WT), WAS knock out (KO)-CD4<sup>+</sup> TEM cells exhibited increased Simpson index and decreased D50 index (P <0.05); The rank abundance curve of KO-CD4<sup>+</sup> TEM cells was shorter and steeper than that of WT, and the angle of <sup>q</sup>D and q in KO-CD4<sup>+</sup> TEM cells was lower than that of WT, while these indexes showed few changes between WT and KO chimeric mice in the CD8<sup>+</sup>TCM population. …”
-
26603
Acceleration of nephron maturation and reduction of cap mesenchyme at E18.5 in Bmp7 knockout kidneys.
Published 2013“…<p>(<b>A</b>) Pregnant mothers bearing Bmp7<sup>LacZ/fl</sup>;Gt(ROSA)26Sor<sup>CreERT2</sup> and Bmp7<sup>+/fl</sup>;Gt(ROSA)26Sor<sup>CreERT2</sup> embryos were administered tamoxifen at E12.5, and sacrificed at E18.5. …”
-
26604
Northern blot analysis of riRNA.
Published 2016“…The level of rRNA markedly decreased in the stationary phase. [C] <i>E</i>. <i>coli</i> BW25113 was grown in M9-glucose medium, and in the middle of exponential phase, total RNA was prepared using Isogen and subjected to Northern blot analysis using a series of Northern probes (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0163057#pone.0163057.t001" target="_blank">Table 1</a>, probes N01 to N10). riRNA was detected using two specific probes, probe-N3 and probe-N4 (for probes see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0163057#pone.0163057.t001" target="_blank">Table 1</a>; and for primers used for amplification of these probes, see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0163057#pone.0163057.s005" target="_blank">S2 Table</a>). …”
-
26605
<strong>Bull trout streamflow and temperature linear SCR model</strong>
Published 2023“…These extremes provided a unique opportunity to retrospectively compare bull trout survival and migration under potential climate change scenarios. …”
-
26606
Robotic-Assisted Median Arcuate Ligament Release With Celiac Artery Lysis and Celiac Ganglion Neurolysis
Published 2020“…<a href="https://doi.org/10.1016/j.jvs.2008.12.078"><em>J Vasc Surg</em>. 2009;50:124-133.…”
-
26607
Table_8_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
26608
Table_1_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
26609
Table_6_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
26610
Table_10_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
26611
Table_2_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
26612
Attention reduces decision uncertainty under high cognitive demand.
Published 2025“…Yellow: increased, dark grey: decreased, light grey: unchanged. (M) Bar plots show the percentage of glomeruli exhibiting a change in response for cued vs. un-cued trials. …”
-
26613
Phenotypic characterization of <i>CsIVP</i>-RNAi transgenic plants.
Published 2020“…Scale bars represent 2 cm in panels A, D–J, and P; 2 mm in panel K; 200 μm in panels L–O; 50 μm in panels L’–O’; and 100 μm in panels R–U. …”
-
26614
P4HA3 deficiency increased sensitization to immune checkpoint inhibitors and P4HA3 could predict the clinical therapeutic effect of PD-1 inhibitor (Camrelizumab).
Published 2024“…(B) P4HA3 deficiency inhibited proliferation ability of MDA-MB-231, HCT116 and A549 cell lines by EdU assay. Scale bar: 50 μm. …”
-
26615
Table_7_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
26616
Table_13_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
26617
Table_12_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
26618
Living 3,4-Polymerization of Isoprene by Cationic Rare Earth Metal Alkyl Complexes Bearing Iminoamido Ligands
Published 2011“…The sterically crowded complexes <b>1</b>−<b>3</b> give a mixture of 3,4- and <i>trans</i>-1,4-polyisoprenes (3,4-selectivities: 48−82%, <i>trans</i>-1,4-selectivities: 50−17%), whereas the less sterically demanding complexes <b>4</b>−<b>6</b> show high 3,4-selectivities (3,4-selectivities: 90−100%). …”
-
26619
DataSheet1_Insights into the reactivity and lithium plating mechanisms of ultra-thin metal oxide coatings for anode-free solid-state lithium metal batteries.docx
Published 2023“…Increasing Al<sub>2</sub>O<sub>3</sub> thickness decreases the practical current density compared to unmodified Cu (30 µA/cm<sup>2</sup>), but increasing ZnO thicknesses can double or triple this value. …”
-
26620
Table_14_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”